Trial Information

Summary: SSRI Versus Bupropion in High-Risk Major Depressive Disorder

The Department of Neuroscience at the New York State Psychiatric Institute is conducting a research study on the prevention of suicidal behavior in Major Depressive Disorder using medications, and is looking for people interested in participating. The goal of our study is to compare the effect of Wellbutrin (bupropion) versus Paxil (paroxetine) on the vulnerability to suicidal behavior during a 6-month period following a Major Depressive Episode. Both Wellbutrin and Paxil are antidepressants which have been approved by the Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder.

We are offering free outpatient medication monitoring visits at the Neuroscience Clinic for a period of 6 months.

If you are interested, or have a family member who is suffering from Major Depressive Disorder, and would like further information, please call.

Inclusion Criteria

• Between 18 and 75 years old
• Currently in a Major Depressive Episode
• History of a past suicide attempt or current suicidal ideation
• Must live within the New York City metro area, since patients are required to come in regularly for psychopharmacological treatment visits

Exclusion Criteria

• History of Bipolar Disorder
• Contraindication to Paxil or Wellbutrin

If you would like to learn more about participating in this study, please send an e-mail message using the form below.